Últimas noticias sobre Tharimmune (NASDAQ:THAR) Bolsa

Tharimmune

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Tharimmune Inc

Tharisa PLC

Goldman Sachs analyst Ryan Nash maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Buy and raises the price target from $29 to $33.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on Regions Finl, Raises Price Target to $33

Goldman Sachs analyst Gabriela Borges maintains Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) with a Neutral and raises the price target from $19 to $21.

PYCR

Goldman Sachs Maintains Neutral on Paycor HCM, Raises Price Target to $21

Goldman Sachs analyst Ryan Nash maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Neutral and raises the price target from $216 to $243.

Goldman Sachs Maintains Neutral on M&T Bank, Raises Price Target to $243

Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) reported better-than-expected third-quarter results and raised its 2024 <a href="https://www.benzinga.com/quote/bbwi/earnings">outlook on Monday.</a>
BBWI&#8217;s third-quarter adjusted earnings per share of 49 cents, beating the analyst consensus of 47 cents. Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, above the street view of $1.579 billion.
Gina Boswell, CEO of Bath &amp; Body Works, commented, &#8220;Our strong results exceeded the high end of our net sales and earnings per diluted share guidance. As a result, we are raising our full-year guidance to fully reflect this outperformance.&#8221;
The company raised fiscal 2024 guidance and now expects net sales to decline 2.5% – 1.7% (prior view: decline of 4% – 2%), including a 100-basis-point headwind from the 53rd week in 2023. Adjusted earnings per share are projected at $3.15 – $3.28 (prior view $3.06 – $3.26) versus the $3.18 consensus.
Bath &amp; Body Works shares gained 16.5% to close at $35.78 on Monday.
These analysts made changes to their price targets on Bath &amp; Body Works following earnings announcement.
<ul>
<li>Piper Sandler analyst Korinne Wolfmeyer maintained Bath &amp; Body Works with a Neutral and raised the price target from $35 to $36.</li>
<li>Barclays analyst Adrienne Yih maintained Bath &amp; Body Works with an Underweight and raised the price target from $28 to $34.</li>
</ul>
Considering buying BBWI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-1024x562.png" alt="" class="wp-image-665566" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

Earnings

Markets

Trading Ideas

BBWI

Bath & Body Works Analysts Boost Their Forecasts After Strong Earnings

Emerald is a leading commercial vehicle manufacturer and seller of refrigerated trucks and vans
The refrigerated Class 3 EV box truck opens new rapidly expanding categories for home delivery, frozen food, grocery and beverage transportation
 &nbsp;
BREA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- <a href="https://www.globenewswire.com/Tracker?data=wFgf3qyya1KMke66r447VNDvrYRea54HMKKRkEIQo7Ly6CoQ822jOQuk85LNxNhZooU03MseZ8fDjALtlgbzIKIt_7OpXeZw6soRqa3qwxk=">Mullen Automotive, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) ("Mullen" or the "Company"), an electric vehicle ("EV") manufacturer, announces today that <a href="https://www.globenewswire.com/Tracker?data=_KqftE2Zw2BKCjE93TpWGt5-j6V6zVcnf-xlK3C_70G2VYB_cBF1YF-BHGPizrPq3GQMdfRLSGcKNe4KxVHmMzA-m4CuMgQqqHWVr8EjgONJBA1I_k_zte6g4XM-yxYU7UW6JQJchokpGnydx1lX_A==">Emerald Transportation Solutions</a> ("Emerald"), a premier commercial refrigeration ("reefer") vehicle upfitter, is working with the Papé Group ("Papé") to develop an advanced reefer upfit for the Mullen THREE, a Class 3 all-electric truck. The refrigerated Class 3 EV box truck opens new rapidly expanding categories for home delivery, frozen food, grocery and beverage transportation.

MULN

Mullen Announces  Emerald Transportation Solutions Is Working With The Papé Group To Develop An Advanced Reefer Upfit For The Mullen THREE, Class 3 All-Electric Truck

Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) will be reporting its third-quarter earnings on Tuesday. Wall Street expects $2.05 in EPS and $24.65 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=DELL" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 93.61% over the past year, 19.48% over the past month.
Let&#8217;s look at what the charts indicate for Dell stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/24/11/42189449/how-to-earn-500-a-month-from-dell-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Dell Stock Ahead Of Q3 Earnings</a>
<h2 class="wp-block-heading">Dell Technical Setup Ahead Of Q3 Earnings&nbsp;</h2>
Dell stock is showcasing a strong bullish trend, with its share price at $144.16 comfortably above the five-day, 20-day and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM.png" alt="" class="wp-image-665421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
This upward momentum is reinforced by the eight-day simple moving average (SMA) of $137.40, the 20-day SMA at $134.40 and the 50-day SMA at $126.41, all pointing to continued bullish strength. 
Additionally, the stock remains well above its 200-day SMA of $122.23, underscoring long-term upward momentum.
However, while the Moving Average Convergence Divergence (MACD) at 4.36 confirms the bullish trend, and the RSI of 66.17 indicates strong buying momentum, the RSI&#8217;s proximity to overbought territory suggests a risk of bearish consolidation. 
Slight selling pressure also hints at potential near-term volatility. While the trend remains firmly bullish, investors should monitor for signs of cooling off as the stock approaches overbought levels.
<h2 class="wp-block-heading">Analysts See 7% Upside</h2>
Ratings &amp; Consensus Estimates: <a href="https://www.benzinga.com/quote/DELL/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Dell stock stands at a Buy currently with a price target of $121.73. Recent analyst ratings from Evercore ISI Group, Wells Fargo and Morgan Stanley suggest an average price target of $154.67 for Dell stock implying a 7% upside.
Price Action: Dell stock closed the trading day Monday at $144.16, down 0.03%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42185644/us-stocks-may-have-a-slow-start-as-trumps-tariff-threat-begins-to-thwart-relief-rally-analysts-remain-positive-on-market-breadth-ai-linked-sectors-and-stocks">US Stocks May Have A Slow Start As Trump&#8217;s Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

DELL

Dell's 93% Rally Hits Q3 Crossroads – What's Next For The Stock?

Canopy Growth Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) announced on Tuesday that its board of directors has named Luc Mongeau as the company's next chief executive officer, effective Jan. 6, 2025.
Mongeau, a CPG veteran and board member at the Canadian cannabis giant, succeeds CEO David Klein, who announced his plans to retire in August.
Klein, who <a href="https://www.benzinga.com/markets/cannabis/24/08/40417074/head-of-canadian-cannabis-giant-canopy-growth-to-retire-at-the-end-of-this-fy">joined</a> Canopy Growth in January 2020, led the Ontario-based company through transformation and development to meet opportunities within the global cannabis market.
&#8220;Under his leadership, the company established a foundation for multi-market cannabis leadership through its transformation to an asset-light model in Canada and across a range of international markets, including Germany,&#8221; the company said in a press release. &#8220;In addition, Mr. Klein oversaw the launch and advancement of Canopy USA as a first-of-its-kind structure to offer the Company's shareholders unique exposure to the rapid growth and opportunity presented by the U.S. cannabis market ahead of federal permissibility.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40419783/canopy-growth-ceo-departure-leaves-nasdaq-listed-company-poised-for-profit-surge-what-investors-">Canopy Growth CEO Departure Leaves Nasdaq-Listed Company Poised For Profit Surge &#8211; What Investors Need To Know</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">New CEO</h3>
Mongeau, who has over 25 years&#8217; experience as a senior executive, has most recently served as the CEO of North America&#8217;s e-commerce provider for residential and commercial furniture ESolutions Furniture, formerly Bestar-Bush. He previously held the role of president for Weston Foods as well as president of Mars Petcare North America.
Mongeau joined Canopy as an observer in early 2023 and as a board member in Feb. 2024.
The new appointment comes simultaneously with the company's influence extending in the U.S. via Canopy USA, LLC.
The new U.S.-domiciled holding company <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/10/29418334/this-is-how-its-done-why-is-canopys-us-consolidation-plan-blueprint-for-other-canad">first introduced</a> in 2022, represents Canopy Growth's strategy for capturing the U.S. cannabis market. The business strategy, which included acquisitions of Wana Brands and Jetty, as well as holding a minority stake in TerrAscend Corp. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TSND#TSX">TSND</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTCQX">TSNDF</a>), also includes the acquisition of Acreage Holdings, Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRG#CSE">ACRG</a>, ACRG.B.U)) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ACRHF#OTCQX">ACRHF</a>, ACRDF)) which is expected to close in early 2025, according to Canopy.
<h3 class="wp-block-heading">What's Next</h3>
Mongeau will continue serving as a member of the board in his new role as CEO.
To support an efficient transition, Klein will continue in his role as CEO and a director on the board until the effective date of Mongeau&#8217;s appointment as CEO.
On Jan. 6, 2025, Klein will step down as a member of the board and will shift into a special advisor role until Aug. 31, 2025.
&#8220;I am honored to lead Canopy Growth into this exciting next chapter, and I am confident that our vision, dedication to our consumers, and the commitment of our team members will continue to position us for long-term success and value creation,&#8221; Mongeau said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a></li>
</ul>
<h3 class="wp-block-heading">CGC Price Action</h3>
Canopy Growth's shares traded 0.2120% lower at $4.1412 per share during the pre-market session on Tuesday morning.

Cannabis

ACRHF

CSE:ACRG

TSNDF

TSX:TSND

TSX:WEED

WEED

Canopy Growth Names New CEO Who Will Succeed David Klein Amid US Expansion

Analog Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) stock traded higher Tuesday after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42185542/analog-devices-reports-fourth-quarter-and-fiscal-2024-financial-results" rel="noreferrer noopener">fiscal fourth-quarter&nbsp;results</a>.
The company&#8217;s revenue declined 10% year-on-year to $2.44 billion, beating the analyst consensus estimate of $2.40 billion. Adjusted EPS of $1.67 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.64</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42186138/taiwan-semis-growth-fuels-us-rise-to-second-in-chipmaking" rel="noreferrer noopener">Taiwan Semi&#8217;s Growth Fuels US Rise To Second In Chipmaking: Report</a>
Analog Devices&#8217;&nbsp;Industrial revenue declined&nbsp;by 21% Y/Y&nbsp;to $1.07 billion. Automotive&nbsp;revenue decreased 2%&nbsp;Y/Y&nbsp;to $716.96 million.
Communications revenue declined by 18% to $275.57 million, and Consumer revenue increased by 31% to $379.69 million.
The adjusted gross margin declined by 230 bps to 67.9% as lower revenue weighed on the profits. The adjusted operating margin fell by 360 bps to 41.1%.
Analog Devices held $2.36 billion in cash and equivalents&nbsp;as of November 2, 2024, generating $1.05 billion in operating cash flow.
According to CEO and Chair Vincent Roche, Analog Devices reported revenue, profitability, and earnings per share exceeding its midpoint guidance, reflecting strong business momentum and effective execution. Despite unprecedented inventory challenges leading to a historic revenue decline in fiscal 2024, the company maintained operating margins above 40%, showcasing the resilience of its business model.
Analog Devices&#8217; quarterly cash dividend of $0.92 per outstanding share of common stock will be paid on December 20 to all shareholders of record at the close of business on December 9.
CFO Richard Puccio noted a rebound in bookings during the fourth quarter, especially in the Automotive segment, following a temporary decline in the third quarter. While macroeconomic uncertainties continue to temper recovery, Analog Devices remains cautiously optimistic about achieving significant growth in fiscal 2025.
Outlook: Analog Devices expects fiscal first-quarter 2025 revenue of $2.35 billion, +/- $100&nbsp;million, versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $2.34 billion</a>. The company projects adjusted EPS of $1.53,&nbsp;+/-$0.10, against the consensus of $1.56.
Price Action: ADI stock traded higher by 5.47% at $235.80 premarket at&nbsp;the last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137930/boeing-secures-238-billion-deal-for-advanced-kc-46a-tankers" target="_blank" rel="noreferrer noopener">Boeing Secures $2.38 Billion US Air Force Deal for Advanced KC-46A Tankers</a></li>
</ul>

Equities

Guidance

Dividends

Movers

Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook & More

Xiaomi Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) is set to launch its own mobile processor for future smartphones, aiming to lessen its dependency on foreign suppliers like Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) and MediaTek Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDTKF#OTC">MDTKF</a>). 
What Happened: This strategic move aligns with Beijing&#8217;s push for local firms to minimize reliance on foreign technology. Xiaomi&#8217;s initiative comes amid a broader trend of tech giants investing in semiconductor development, a critical area in the ongoing tech race with the United States, according to&nbsp;<a href="https://www.bloomberg.com/news/articles/2024-11-26/xiaomi-readies-own-mobile-chip-pressuring-mediatek-and-qualcomm">Bloomberg</a> on Tuesday, the chip&#8217;s mass production is slated for 2025.
Xiaomi&#8217;s chipmaking efforts could potentially challenge its current manufacturing partner, Taiwan Semiconductor Manufacturing Co., (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) especially as the latter faces increasing pressure from U.S. authorities regarding its dealings with Chinese clients.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42154224/weekend-round-up-ai-dominates-headlines-with-nvidia-elon-musk-and-hollywoods-big-names?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Weekend Round-Up: AI Dominates Headlines With Nvidia, Elon Musk, And Hollywood&#8217;s Big Names</a>
In addition to mobile processors, Xiaomi&#8217;s investment in research and development is projected to rise to 30 billion yuan in 2025, focusing on artificial intelligence and operating system enhancements. Chairman and CEO&nbsp;Lei Jun&nbsp;announced these plans during a recent company event, emphasizing the importance of core technologies, Bloomberg reported.
Why It Matters: Previously, Xiaomi launched its first in-house chip &#8220;Surge S1,&#8221; a mid-range system-on-chip (SoC) in 2017 for its Mi 5C smartphone. However, the adoption was limited due to competition from Qualcomm and MediaTek.
A reported attempt to develop the &#8220;Surge S2&#8221; chip was halted due to production delays and technical hurdles in 2020, as <a href="https://www.gizmochina.com/2020/03/18/xiaomis-surge-chip-development-reportedly-abandoned-shifting-focus-to-low-power-bl-rf-chips/">per</a> Gizmochina.
The development of Xiaomi&#8217;s in-house chips is a significant step in China&#8217;s broader strategy to become self-reliant in critical technology sectors. This move is part of a larger trend where <a href="https://www.benzinga.com/24/11/42153854/apples-future-ventures-huaweis-new-chip-and-googles-antitrust-woes-this-week-in-appleverse">Chinese tech companies are increasingly investing in semiconductor technology</a> to reduce dependence on foreign suppliers. Recently, in a move to challenge the dominance of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Huawei introduced its latest flagship smartphone, the Mate 70, featuring the HarmonyOS Next. This new operating system has been developed entirely in-house, marking a significant step for Huawei in the mobile OS market.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/11/42157390/intels-federal-chips-grant-shrinks-below-8b-as-biden-administration-recalibrates-chips-act-funding-report?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Intel&#8217;s Federal Chips Grant Shrinks Below $8B As Biden Administration Recalibrates CHIPS Act Funding: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by Srikant_Photography on Shutterstock

General

AAPL

GOOG

GOOGL

MDTKF

QCOM

XIACF

Xiaomi Set To Challenge Qualcomm, MediaTek As It Ventures Into Chipmaking Once Again

Millennials are having fewer children than their parents did. While that might <a href="https://www.benzinga.com/personal-finance/24/07/39674955/millennials-slated-to-be-the-richest-generation-in-history-but-they-are-very-ill-prepared-how-wi">work for their personal budgets,</a> experts warn it could drag the economy down for decades.
James Pomeroy, a global economist at HSBC, paints a grim picture. &#8220;What you&#8217;re talking about is these birth rates dropping to very, very low levels, which over the course of time has huge impacts on the economy,&#8221; he told Business Insider. The U.S. birthrate has fallen dramatically – <a href="https://www.cdc.gov/nchs/data/vsrr/vsrr028.pdf">just 11.1 births per 1,000 people</a> in 2022, a 53% drop from 1960. And it's still dropping, around 2% each year.
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>
Why do fewer kids mean trouble? Lower birthrates mean fewer workers in the economy. That has a ripple effect. Todd Buchholz, a former White House economist, explains the challenges. &#8220;You find it more difficult to find somebody to cut your hair, do your nails, work on, set up the X-ray machines at the hospital,&#8221; he said. &#8220;The sheer decrease in the number of people … becomes a problem.&#8221;
Social Security is another big issue. By 2029, all baby boomers will be 65 or older, putting massive pressure on Medicare and Social Security. Buchholz says the system isn't ready. &#8220;We will have a great deal of trouble … figuring out how to pay the retirements. The promised retirement payments for senior citizens … are going to go in vast deficits.&#8221;
See Also: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a>
According to Buchholz, in the 1930s, there were 20 workers for every retiree. If trends continue, Buchholz says the ratio could drop to two workers per retiree. &#8220;That is simply not sustainable,&#8221; he warns.
The cost of living is a major factor for millennials. From housing to education, everything is more expensive. Some millennials are opting out of parenthood entirely. Many are part of the DINK (dual income, no kids) lifestyle, <a href="https://www.benzinga.com/real-estate/24/11/41700720/better-off-redfin-survey-reveals-69-of-millennial-and-gen-z-homeowners-see-wealth-surge-compared-to">choosing to spend their money</a> on vacations, hobbies and luxuries instead of raising children.
Pomeroy says cultural attitudes also play a role. &#8220;I think it&#8217;s a net negative to have fewer children when the choice is between having a child and investing in a new Sony PlayStation,&#8221; he said.
Buchholz agrees, adding that society needs a mindset shift. He suggests reframing the narrative around children. &#8220;People who have children feel that they live more than once,&#8221; he said, highlighting the fulfillment that family can bring.
So what's next? Fixing this problem won't be easy. Government policies like housing reforms or financial incentives could help. But experts say it'll take a long time to see results. America faces a future with fewer kids, fewer workers and tough economic challenges ahead.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

The U.S. Birthrate Has Plunged 53% Since 1960. An HSBC Economist Is Sounding The Alarm

HC Wainwright &amp; Co. analyst Arthur He downgrades Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) from Buy to Neutral and lowers the price target from $20 to $9.

Downgrades

PSTX

HC Wainwright & Co. Downgrades Poseida Therapeutics to Neutral, Lowers Price Target to $9

<ul>
<li>NVDA</li>
<li>ACHR</li>
<li>MSTR</li>
<li>RIVN</li>
<li>RKLB</li>
<li>TSLA</li>
<li>SMCI</li>
<li>$BTC</li>
<li>CORN</li>
<li>LOT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

ACHR

CORN

MSTR

NVDA

RIVN

RKLB

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 26, 2024 (Via Swaggy Stocks)

Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) reported better-than-expected third-quarter financial results and issued fourth-quarter guidance with its <a href="https://www.benzinga.com/quote/SMTC/earnings">midpoint above estimates</a>.
Semtech reported quarterly earnings of 26 cents per share which beat the analyst consensus estimate of 23 cents per share. The company reported quarterly sales of $236.80 million which beat the analyst consensus estimate of $232.06 million.
&#8220;We are very pleased to report broad-based growth across each of our end markets, and particularly in data center, where we project AI-driven product demand to be a long-term and transformational growth engine for Semtech. Our results validate that our customers and target markets are moving toward us and highlight the effectiveness of our initiatives to drive market share gain and SAM expansion,&#8221; said Hong Hou, Semtech&#8217;s president and chief executive officer. &#8220;I believe we have achieved multi-generational roadmap alignment with customers and aspire to become the partner of choice for key technical and product solutions we provide.&#8221;
Semtech shares gained 5% to close at $53.44 on Monday.
These analysts made changes to their price targets on Semtech following earnings announcement.
<ul>
<li>Needham analyst Quinn Bolton reiterated Semtech with a Buy and raised the price target from $50 to $70.</li>
<li>Northland Capital Markets analyst Gus Richard maintained the stock with an Outperform and raised the price target from $46 to $60.</li>
<li>Piper Sandler analyst Harsh Kumar reiterated Semtech with an Overweight and raised the price target from $60 to $75.</li>
<li>Stifel analyst Tore Svanberg maintained the stock with a Buy and boosted the price target from $58 to $65.</li>
</ul>
Considering buying SMTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282-1024x508.png" alt="" class="wp-image-665536" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282-1024x508.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282-768x381.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

SMTC

Semtech Analysts Raise Their Forecasts After Upbeat Earnings

Goldman Sachs analyst John Mackay maintains Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) with a Buy and raises the price target from $32 to $44.

Goldman Sachs Maintains Buy on Kodiak Gas Services, Raises Price Target to $44

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to expand coverage of anti-obesity medications for Americans with <a href="https://www.benzinga.com/wiim/24/11/42186510/novo-nordisk-and-eli-lilly-shares-are-trading-higher-after-the-biden-harris-administration-proposed">Medicare and Medicaid</a>.
What Happened: The government has proposed a new rule to expand access to medications for obesity. In a statement released Monday, the Biden-Harris Administration said Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95% for some enrollees. Approximately 4 million Medicaid enrollees would also gain access to these medications.
&#8220;The President is proud of the fact that the Inflation Reduction Act allows Medicare to negotiate down the price of drugs, a tool that will help Medicare lower the cost of some of the most expensive medications in the program.&nbsp; That power to negotiate drug prices is critical because Americans pay two to three times more than people in other countries for their prescription drugs,&#8221; the White House said in a statement.
The move is part of the Biden-Harris Administration's&nbsp;national strategy on Hunger, Nutrition and Health&nbsp;focused on ending hunger and reducing diet-related diseases such as obesity.&nbsp;
The anti-obesity drug market has expanded in recent years with FDA approval for a new class of drugs like&nbsp;<a href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure">Eli Lilly's Zepbound</a>, which can cost close to $1,000 per month for those paying out-of-pocket. 
One of the main parts of the Biden-Harris Administration&#8217;s strategy involves recognizing the opportunity within Medicare and Medicaid to support access to nutritious foods, obesity counseling and other nutrition-related services.&nbsp;
&#8220;Obesity is a multi-faceted disease and we need to work on all levels from prevention to treatment to address this persistent challenge,&#8221; the White House said.
Eli Lilly&#8217;s Zepbound generated $1.26 billion in sales for the company in its most recent quarter. Eli Lilly said Mounjaro and Zepbound sales in&nbsp;the third quarter&nbsp;were negatively impacted by inventory decreases in the wholesaler channel.&nbsp;
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/42188320/best-buy-says-q3-sales-little-softer-than-expected-on-lower-demand-for-appliances-and-gaming-trims-annual-forecast">Best Buy Says Q3 Sales &#8216;Little Softer Than Expected&#8217; On Lower Demand For Appliances And Gaming, Trims Annual Forecast</a>
LLY Price Action: Eli Lilly shares were up 3.58% at $782.00 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Eli Lilly Stock Is Rising Tuesday: What's Going On?

Goldman Sachs analyst John Mackay maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Buy and raises the price target from $26 to $29.

Goldman Sachs Maintains Buy on Kinder Morgan, Raises Price Target to $29

Cannabis giant Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) announced the latest small batch indica strain by its craft cannabis brand, Broken Coast: Platinum Pavé. This new cultivar is one of the first from Broken Coast&#8217;s state-of-the-art Vancouver Island, BC facility. Platinum Pavé is grown under optimized conditions in single-strain, laboratory-grade rooms. Each batch is precisely pruned, slowly cold cured and rigorously inspected for purity.
"We're excited for consumers to get their hands on this exceptional indica," stated Kevin Anderson, master grower at Broken Coast. "After phenohunting over 500 seeds, we're extremely proud to cultivate a strain with potent THC and a unique terpene profile. With our slow cold curing process, we take pride in preserving trichome density, delivering the purest expression of the Spritzer x Pavé cross to deliver something special."
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41811378/aurora-vs-canopy-tilray-which-nasdaq-listed-cannabis-stock-offers-the-best-growth-p">Aurora vs. Canopy &amp; Tilray: Which NASDAQ-Listed Cannabis Stock Offers The Best Growth Potential?</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Platinum Pavé Higlights</h2>
<ul>
<li>Lineage: Spritzer x Pavé.</li>
<li>Aromas: Sweet, earthy with a potent hint of diesel.</li>
<li>Rich terpene profile featuring: Limonene, Caryophyllene, Linalool.</li>
<li>THC range:&nbsp;Potent and suitable for winding down after a long day or enjoying socially.</li>
</ul>
Despite the laborious process, the team is dedicated to thoughtfully choosing strains and refining their growing and curing techniques to develop the best product possible. Platinum Pavé joins Broken Coast's renowned craft cannabis portfolio, including Cherry Cheesecake, EmergenZ, Sour OG, Holy Grail Kush, Amnesia Haze, and most recent fan favorite, Milk &amp; Cookies.
Craft flower enthusiasts can experience the handcrafted genetics of Broken Coast&#8217;s Platinum Pavé, available in 7g exclusively in British Columbia, with 3.5g whole flower, and in pre-rolls – 3&#215;0.5g and 5&#215;0.5g multipacks coming to Ontario and Alberta in the new year.
Price Action
Tilray shares traded flat at $1.42 during Tuesday's pre-market session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41997646/tilray-joins-german-cannabis-fiesta-with-first-locally-grown-strains">Tilray Joins German Cannabis Fiesta With First Locally Grown Strains</a></li>
</ul>
Courtesy photo

TLRY

Tilray Introduces New Indica Strain With 'Potent THC And A Unique Terpene Profile'

Binance founder and former CEO Changpeng Zhao on Tuesday voiced concerns about the current <a href="https://www.benzinga.com/money/top-meme-coins">state of meme coins</a>, calling their proliferation &#8220;a little weird.&#8221;
What Happened: In a tweet, Zhao clarified he isn't against memes but urged the crypto community to focus on building meaningful blockchain applications.
"Let's build real applications using blockchain," he <a href="https://x.com/cz_binance/status/1861306581758976434">wrote</a>.
Zhao's remarks come amid growing scrutiny of platforms like Pump.fun, which have simplified the process of <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42171439/solana-meme-coin-platform-pump-fun-faces-backlash-over-scandalous-livestreams-but-polymarket-traders-arent-convinced-theyll-go-dark">creating and launching meme coins</a>.
These platforms allow anyone to mint tokens in minutes without requiring identity verification, making them a hotbed for scams and exploitation. 
While designed to attract attention through features like live-streamed token launches, these tools have reportedly spiraled into disturbing displays of violence, fraud, and even animal abuse.
With little to no accountability, such platforms have created fertile ground for exploitation, leaving unsuspecting retail investors at the mercy of bad actors.
A recent report by CoinWire shed further light on the<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42169183/dont-get-fooled-by-the-success-of-dogecoin-shiba-inu-76-of-x-twitter-influencers-promote-dead-meme-coins-study-reveals"> risks associated with meme coins</a>.
Analyzing over 1,500 meme coins promoted by 377 influencers on X (formerly Twitter), the study found that 76% of these tokens eventually become &#8220;dead,&#8221; meaning they lose 90% or more of their value within three months of promotion.
While established meme coins like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) have maintained liquidity and market relevance, the majority of promoted meme coins fail to replicate this success. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42170669/wisdomtree-files-for-xrp-etf-trust-report">WisdomTree Files For XRP ETF Trust: Report</a>
Only 3% of tokens managed to deliver the coveted 10x returns often promised by influencers, with larger influencers faring even worse—tokens they promoted delivered an average negative return of 89% within three months.
Zhao's comments align with a growing push within the crypto community for more responsible behavior from platforms and influencers. 
Eric Chen, CEO and co-founder of Injective Labs, noted that influencers in the crypto space span a wide range of strategies, from promoting speculative tokens to offering more qualitative insights.
"While some influencers undoubtedly engage in questionable promotions, it's important not to generalize their actions to the entire community," Chen told Benzinga. 
He emphasized that token performance depends on multiple factors, including broader market sentiment, whale activity, and retail investor participation. 
However, Chen cautioned that influencers wield significant power over market trends and should act responsibly.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42166673/drug-cartels-use-tether-and-bitcoin-to-launder-millions-court-documents-reveal">Drug Cartels Use Tether And Bitcoin To Launder Millions, Court Documents Reveal</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Binance Founder Changpeng Zhao Says Meme Coins Are Getting 'A Little Weird' — But Dogecoin, Shiba Inu Aren't The Culprits

Goldman Sachs analyst Ryan Nash maintains KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) with a Buy and raises the price target from $20 to $23.

Goldman Sachs Maintains Buy on KeyCorp, Raises Price Target to $23

VCIG

VCI Global Regains Nasdaq Compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock is on the move Friday as investors prepare for the company&rsquo;s shares to undergo a reverse split when markets close today.



Tharimmune&nbsp;is enacting a <a href="https://www.nasdaq.com/press-release/tharimmune-announces-1-for-15-reverse-stock-split-2024-05-22">one-for-15 reverse stock split</a> for THAR shares. The shares will still trade under the THAR ticker but will switch to the new CUSIP number 432705309.



Tharimmune&nbsp;notes that this split will see it consolidate every 15 shares of its stock into a single share. The company says that this will leave it with 785,978 shares of THAR stock after the reverse split is complete.



<h2>What&rsquo;s Behind the THAR Reverse Stock Split?</h2>



Tharimmune&nbsp;is moving forward with this reverse stock split to boost the price of its shares. The company wants to boost its share price to reach the $1 minimum bid required to remain on The Nasdaq Capital Market. The stock was trading for 33 cents per share when markets closed yesterday.



Tharimmune&nbsp;wants to remain listed as it&rsquo;s still only a clinical-stage biotechnology company. That means it doesn&rsquo;t have a product to sell just yet. Remaining publicly listed is its goal leading up to a potential drug candidate release.



THAR stock is up 3.7% as of Friday morning ahead of the reverse split. However, the company&rsquo;s shares were down 34.5% year-to-date when markets closed on Thursday.



Investors will find more of the most recent stock market stories below!



We have all of the hottest stock market news traders need to know about on Friday! A few examples include what&rsquo;s happening with shares of Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock as well as the biggest pre-market stock movers this morning. All of this news is ready at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-may-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Tharimmune (THAR) Stock Moving Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101.



SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors.



The bad news for Sensei Biotherapeutics comes from its <a href="https://www.nasdaq.com/press-release/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation">results in this trial</a>. The company notes that only a few patients of the 34 treated showed signs of improvement. That doesn&rsquo;t seem to be sitting well with SNSE stockholders today.



Dr.&nbsp;Shiraj Sen, a principal&nbsp;investigator in the SNS-101 study, said the following about the results.




&ldquo;The data show encouraging signs of clinical activity in a heterogeneous population of patients with advanced solid tumors, where you typically wouldn&rsquo;t expect to see clinical responses, especially in microsatellite stable colorectal and endometrial tumors.&rdquo;




<h2>SNSE Stock Market Movement on Friday</h2>



SNSE stock is seeing a decent amount of trading on Friday morning. This has more than 160,000 shares of the stock changing hands as of this writing. That&rsquo;s closing in on its daily average trading volume of about 208,000 shares.



SNSE stock is down 39.8% as of Friday morning. However, shares were up 83.5% year-to-date when markets closed yesterday.



Investors looking for more of the most recent stock market stories are in luck!



We have all of the hottest stock market news traders need to know about on Friday! That includes what&rsquo;s going on with shares of Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock, Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>)&nbsp;stock and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock today. All of this info is good to go at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) stock is falling hard on Friday following the release of new clinical trial data for its metastatic pancreatic cancer treatment.



The company is <a href="https://finance.yahoo.com/news/verastem-oncology-announces-positive-initial-210100621.html">conducting a Phase 1/2 clinical trial</a> of avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel. The results were positive and that initially saw VSTM stock rally higher this morning.



However, investors quickly noticed the safety data included in these results. 19 of the 41 patients in the trial suffered from emergent serious adverse events. That includes 11 with grade &ge;3 events. Among these were blood bilirubin increase, biliary obstruction, febrile neutropenia, pulmonary embolism, sepsis, anaemia, pneumoperitoneum, septic shock, skin infection, malignant neoplasm progression and vomiting.



John Hayslip, Chief Medical Officer at Verastem, said the following about the clinical trial results.




&ldquo;Metastatic pancreatic cancer continues to be a challenging cancer to treat and these data support the intent behind the Therapeutic Accelerator Award that we received from PanCAN to develop new therapies faster and more efficiently than in historical studies.&rdquo;




<h2>VSTM Stock Movement on Friday</h2>



VSTM stock is experiencing heavy trading on Friday alongside this data. That has more than 10 million shares traded as of this writing. This is a massive surge compared to its daily average trading volume of about 134,000 shares.



VSTM stock is down 61.7% as of Friday morning!



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Friday! Among that is what has shares of Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>), Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) and Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) stock moving today. All of this news is available down below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-verastem-vstm-stock-down-62-today/">Why Is Verastem (VSTM) Stock Down 62% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Verastem (VSTM) Stock Down 62% Today?

Tharimmune announces $2.08M private placement

Tharimmune files for 1M common stock offering by selling stockholders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) just reported results for the second quarter of 2024.<ul><li>Tharimmune reported earnings per share of -$2.42.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/thar-stock-earnings-tharimmune-for-q2-of-2024/">THAR Stock Earnings: Tharimmune Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024

Tharimmune ( ($THAR) ) has provided an announcement. Tharimmune, Inc. has secured an exclusive license from Intract Pharma to develop an oral versi...

Tharimmune Expands Immunology Pipeline with Intract License

Tharimmune ( ($THAR) ) has shared an announcement. Tharimmune, Inc. has announced its intent to acquire Intract Pharma Limited, aiming to purchase ...

Tharimmune Announces Intent to Acquire Intract Pharma

Tharimmune (THAR) presented new TH104 Phase 1 data at the American College of Gastroenterology 2024 Annual Scientific Meeting, underway in Philadel...

Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting

Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in ...

Comments

Tharimmune

Noticias

Últimas noticias sobre Tharimmune (NASDAQ:THAR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL